felin
infecti
periton
fip
felin
coronaviru
fcov
induc
diseas
almost
invari
fatal
median
life
expect
measur
day
current
treatment
option
best
palli
object
studi
evalu
panel
nineteen
candid
compound
antivir
activ
fcov
vitro
determin
viabl
candid
therapi
resazurinbas
cytopath
effect
inhibit
assay
detect
viabl
cell
reduct
substrat
resazurin
fluoresc
resorufin
develop
screen
compound
antivir
efficaci
fcov
plaqu
reduct
viru
yield
reduct
assay
perform
confirm
antivir
effect
candid
compound
identifi
screen
possibl
antivir
mechan
action
compound
investig
use
virucid
suspens
assay
cpe
inhibit
ifabas
time
addit
assay
three
compound
chloroquin
mefloquin
hexamethylen
amilorid
demonstr
mark
inhibit
viru
induc
cpe
low
micromolar
concentr
orthogon
assay
confirm
inhibit
cpe
associ
signific
reduct
viral
replic
select
indic
calcul
base
vitro
cytotox
screen
reduct
extracellular
viral
titr
chloroquin
mefloquin
hexamethylen
amilorid
respect
preliminari
experi
perform
inform
antivir
mechan
compound
demonstr
three
act
earli
stage
viral
replic
result
suggest
direct
act
antivir
compound
deriv
warrant
investig
clinic
use
cat
fip
elsevi
bv
right
reserv
number
compound
demonstr
inhibitori
effect
viru
vitro
barlough
shacklett
hsieh
et
al
keyaert
et
al
littl
publish
data
regard
use
treat
fip
broad
spectrum
antivir
ribavirin
demonstr
vitro
efficaci
provid
limit
clinic
benefit
produc
toxic
cat
weiss
et
al
recent
small
studi
involv
experiment
infect
cat
treatment
chloroquin
drug
demonstr
vitro
antivir
efficaci
associ
mild
improv
clinic
sign
howev
statist
signific
differ
surviv
time
compar
untreat
cat
takano
et
al
efficaci
safe
antivir
therapeut
desper
need
fip
treatment
modern
antivir
drug
discoveri
often
involv
high
throughput
screen
vast
chemic
librari
larg
scale
unfocus
screen
expens
beyond
reach
companion
anim
medicin
altern
approach
utilis
focus
screen
strategi
enrich
screen
librari
compound
consid
like
antivir
effect
base
prior
knowledg
pharmacodynam
viral
life
cycl
focus
screen
panel
may
consist
compound
relat
demonstr
effect
challeng
viru
demonstr
effect
close
relat
virus
current
studi
screen
compound
previous
demonstr
antivir
activ
coronavirus
rna
virus
antivir
activ
fcov
use
optimis
resazurinbas
cpe
inhibit
assay
cytotox
compound
determin
prior
screen
use
sequenti
resazurinand
srbbase
assay
determin
optim
minim
toxic
test
concentr
enabl
calcul
select
indic
antivir
effect
compound
identifi
screen
confirm
plaqu
reduct
viru
yield
reduct
assay
virucid
suspens
assay
time
addit
assay
provid
initi
inform
stage
viral
replic
target
potenti
mechan
action
crandel
ree
felin
kidney
crfk
cell
line
propag
dulbecco
modifi
eagl
medium
dmem
sigmaaldrich
castl
hill
nsw
australia
supplement
fb
sigmaaldrich
humidifi
incub
co
air
two
strain
fcov
fipv
wsu
fecv
wsu
acquir
american
type
cultur
collect
virginia
usa
use
fcov
origin
isol
mesenter
lymph
node
intestin
wash
year
old
femal
domest
shorthair
cat
die
acut
haemorrhag
gastroenter
fcov
origin
isol
liver
spleen
lung
case
neonat
death
male
persian
kitten
mckeirnan
et
al
pathogen
studi
two
isol
shown
highli
virul
reliabl
caus
sign
classic
fip
follow
oronas
inocul
caus
low
grade
fever
mild
enter
sign
fip
pedersen
despit
dissimilar
vivo
biolog
properti
two
isol
two
similar
vitro
properti
immortalis
cell
line
compound
select
test
panel
base
report
vitro
antivir
properti
coronavirus
rna
virus
see
supplementari
materi
detail
compound
test
screen
concentr
shown
tabl
stock
solut
prepar
dissolv
compound
ultrapur
water
dmso
sigmaaldrich
compound
steril
filter
mm
regener
cellulos
filter
corn
inc
corn
ny
usa
aliquot
steril
singl
use
microtub
sarstedt
numbrecht
germani
store
maximum
month
use
determin
appropri
screen
concentr
cytotox
test
compound
determin
use
sequenti
resazurin
sulforhodamin
b
assay
resazurinbas
assay
perform
antivir
screen
assay
except
compound
ad
ml
volum
infect
step
perform
srb
assay
cell
immedi
fix
post
fluoresc
data
acquisit
decant
cultur
media
invert
plate
ad
trichloroacet
acid
h
srb
stain
previous
describ
vichai
kirtikara
except
srb
use
stain
follow
solubilis
bound
dye
measur
use
fluostar
omega
micropl
reader
bmg
labtech
mornington
australia
viabil
compar
untreat
control
test
compound
concentr
select
subsequ
antivir
screen
result
cell
viabil
greater
compound
show
mark
moder
mild
antivir
effect
defin
show
inhibit
cpe
respect
compound
demonstr
mark
cpe
inhibit
classifi
candid
compound
select
characteris
use
resazurinbas
cpe
inhibit
assay
concentrationrespons
experi
conduct
serial
dilut
identifi
candid
compound
nine
concentr
per
compound
enabl
calcul
select
index
repeat
cytotox
screen
perform
concurr
treatment
perform
triplic
repeat
three
independ
experi
data
export
microsoft
excel
calcul
cell
viabil
cpe
inhibit
accord
formula
describ
data
analysi
conduct
graphpad
prism
inhibitori
concentr
cytotox
concentr
valu
calcul
use
inbuilt
nonlinear
curv
fit
function
follow
log
transform
compound
concentr
select
index
si
compound
calcul
accord
follow
formula
confirmatori
assay
plaqu
reduct
viru
yield
reduct
assay
perform
confirm
antivir
effect
candid
compound
identifi
use
cpe
inhibit
assay
viru
yield
reduct
assay
perform
plate
sarstedt
well
seed
cell
well
ml
plate
kept
room
temperatur
min
co
air
h
prior
addit
test
compound
compound
dilut
dmem
requir
concentr
ml
ad
well
cell
incub
co
air
addit
h
prior
infect
fcov
moi
ml
dmem
cell
incub
h
co
h
postinfect
hpi
cell
monolay
visual
assess
cpe
use
olympu
invert
phasecontrast
microscop
olympu
melvil
ny
usa
cultur
media
collect
store
viru
titrat
untreat
infect
cell
untreat
uninfect
cell
treat
uninfect
cell
includ
control
latter
control
includ
allow
assess
morpholog
chang
cell
due
compound
treatment
titrat
extracellular
viru
harvest
hpi
perform
use
method
describ
mcdonagh
et
al
treatment
time
point
perform
triplic
repeat
two
independ
experi
result
repres
mean
ae
se
plaqu
reduct
assay
perform
plate
corn
cell
seed
densiti
cell
well
ml
held
room
temperatur
min
prior
incub
co
air
h
time
monolay
approxim
confluent
cultur
media
discard
replac
ml
dmem
supplement
fb
plu
ml
variou
concentr
test
compound
dmem
ml
dmem
control
well
use
five
six
concentr
per
compound
exposur
compound
h
cell
infect
pfu
well
fcov
ml
dmem
viru
allow
adsorb
min
plate
rock
everi
min
ensur
even
distribut
inoculum
cultur
media
discard
min
cell
overlaid
ml
carboxymethylcellulos
fb
dmem
contain
concentr
compound
present
prior
infect
cell
fix
stain
wv
crystal
violet
hpi
prior
manual
plaqu
count
rel
plaqu
number
calcul
treatment
valu
untreat
control
defin
treatment
perform
duplic
repeat
three
independ
experi
data
repres
mean
ae
se
virucid
suspens
assay
perform
assess
virucid
effect
test
compound
assay
perform
except
viru
mix
incub
test
compound
prior
infect
stock
fcov
dilut
dmem
pfu
ml
mix
equal
volum
test
compound
dilut
dmem
test
concentr
use
screen
control
viru
suspens
mix
dmem
contain
equal
concentr
dmso
test
sampl
viru
suspens
incub
h
room
temperatur
serial
dilut
dmem
infect
cell
pfu
well
ml
follow
serial
dilut
viru
cell
expos
test
compound
concentr
greater
log
lower
concentr
previous
shown
antivir
effect
experi
perform
triplic
repeat
two
independ
experi
data
repres
mean
ae
se
modif
resazurinbas
cpe
inhibit
assay
perform
assess
effect
time
compound
addit
antivir
efficaci
identifi
compound
cpe
inhibit
assay
perform
previous
describ
except
test
compound
ad
variou
time
point
infect
select
time
point
h
prior
infect
concurr
infect
h
postinfect
treatment
perform
triplic
repeat
three
independ
experi
data
repres
mean
ae
se
elucid
stage
viral
replic
affect
compound
effect
time
addit
viral
antigen
express
examin
cell
seed
densiti
cell
well
ml
plate
mclear
greiner
bioon
seed
plate
kept
room
temperatur
min
incub
co
air
h
prior
first
timepoint
compound
addit
compound
ad
ml
duplic
well
differ
time
point
prior
concurr
postinfect
cell
infect
fcov
moi
ml
mock
infect
ml
dmem
infect
period
h
infect
period
h
select
base
report
one
step
growth
curv
fcov
rottier
et
al
hpi
measur
end
infect
period
cell
fix
formaldehyd
pb
permeabilis
ice
cold
methanol
viral
antigen
detect
biotinyl
antifcov
antibodi
custom
monoclon
intern
sacramento
ca
usa
visualis
streptavidinconjug
alexafluor
life
technolog
mulgrav
vic
australia
enabl
accur
segment
cell
stain
whole
cell
stain
hc
cell
mask
blue
life
technolog
dapi
life
technolog
enhanc
nuclear
visualis
fluoresc
imag
perform
use
bd
pathway
bioimag
bd
bioscienc
franklin
lake
nj
usa
imag
well
acquir
use
object
na
use
montag
laser
autofocu
perform
montag
frame
hc
cell
mask
bluedapi
imag
acquir
ex
bp
em
lp
filter
alexa
fluor
imag
acquir
ex
bp
em
lp
filter
imag
analysi
perform
use
free
opensourc
imag
analysi
softwar
cellprofil
wwwcellprofilerorg
data
export
fc
express
imag
cytometri
version
de
novo
softwar
lo
angel
ca
usa
analysi
treatment
perform
duplic
data
repres
mean
ae
sd
assess
efficaci
differ
fcov
strain
identifi
candid
compound
test
fcov
use
resazurinbas
cpe
inhibit
assay
assay
perform
describ
except
cell
infect
either
fcov
moi
treatment
perform
triplic
repeat
three
independ
experi
data
repres
mean
ae
se
three
nineteen
test
compound
show
mark
inhibit
viru
induc
cpe
fig
select
characteris
pretreat
chloroquin
mm
mefloquin
mm
hexamethylen
amilorid
mm
result
inhibit
cpe
respect
two
compound
glycyrrhiz
acid
mm
cinanserin
mm
display
mild
antivir
effect
reduct
cpe
respect
compound
demonstr
limit
inhibitori
effect
cpe
includ
among
ineffect
compound
ribavirin
broad
spectrum
antivir
compound
previous
shown
vitro
barlough
scott
weiss
oostromram
limit
extent
vivo
efficaci
fcov
weiss
et
al
well
rfeifnv
previous
shown
vitro
efficaci
fcov
mochizuki
et
al
truyen
et
al
concentrationrespons
studi
conduct
chloroquin
mefloquin
hexamethylen
amilorid
repeat
cytotox
screen
concurr
perform
compound
allow
calcul
select
indic
compound
demonstr
clear
concentrationrespons
effect
test
rang
fig
calcul
si
valu
compound
shown
tabl
viru
yield
reduct
assay
confirm
cpe
inhibit
identifi
screen
associ
mark
reduct
extracellular
viral
titr
determin
extracellular
viru
titr
perform
hpi
result
shown
fig
chloroquin
mefloquin
consider
differ
result
concentrationrespons
curv
hpi
hexamethylen
amilorid
shape
curv
similar
time
point
differ
concentrationrespons
curv
two
time
point
reflect
valu
increas
valu
chloroquin
mefloquin
hpi
compar
hpi
hexamethylen
amilorid
valu
similar
time
point
tabl
plaqu
reduct
assay
confirm
find
cpe
inhibit
viru
yield
reduct
assay
pretreat
chloroquin
mefloquin
hexamethylen
amilorid
result
concentrationdepend
decreas
plaqu
number
high
concentr
complet
inhibit
macroscop
plaqu
format
compound
plaqu
morpholog
similar
treat
untreat
well
howev
plaqu
size
smaller
treat
versu
untreat
well
viru
yield
reduct
assay
cell
monitor
develop
cpe
use
phase
contrast
microscopi
note
infect
uninfect
cell
treat
chloroquin
mefloquin
hexamethylen
amilorid
display
characterist
morpholog
chang
chang
consist
larg
number
variabl
size
cytoplasm
predominantli
perinuclear
inclus
addit
presenc
cell
increas
number
cytoplasm
vacuol
investig
natur
inclus
separ
well
stain
mg
ml
neutral
red
dmem
h
inclus
appear
accumul
vital
dye
neutral
red
follow
suggest
like
dilat
endosomeslysosom
fig
use
virucid
suspens
assay
virucid
effect
seen
chloroquin
mefloquin
hexamethylen
amilorid
infect
viru
suspens
expos
compound
significantli
differ
viru
incub
media
alon
effect
time
addit
antivir
activ
select
compound
assess
use
modif
resazurinbas
cpe
inhibit
assay
ifa
viral
protein
express
base
cpe
inhibit
assay
maximum
antivir
effect
seen
compound
ad
prior
concurr
infect
follow
timedepend
reduct
cpe
inhibit
fig
test
compound
cpe
inhibit
remain
greater
compound
ad
latest
test
time
point
h
postinfect
cpe
inhibit
assay
encompass
multipl
round
viral
replic
elucid
stage
viral
replic
affect
test
compound
singl
replic
cycl
ifabas
assay
conduct
confirm
base
viral
antigen
express
three
compound
possess
antivir
properti
ad
prior
time
infect
furthermor
compound
display
time
addit
depend
reduct
antivir
effect
howev
extent
time
reduct
vari
inhibitori
effect
chloroquin
reduc
base
increas
percentag
fcov
antigen
posit
cell
ad
time
postinfect
fig
similar
result
seen
hexamethylen
amilorid
although
case
signific
increas
number
infect
cell
seen
compound
addit
delay
hpi
contrast
mefloquin
remain
effect
ad
hpi
suggest
may
act
later
stage
viral
replic
chloroquin
hexamethylen
amilorid
efficaci
three
identifi
candid
compound
test
fcov
serotyp
ii
enter
biotyp
fcov
comparison
viru
control
treatment
well
show
fcov
infect
result
pronounc
cpe
h
infect
period
compar
fcov
pretreat
chloroquin
mefloquin
hexamethylen
amilorid
provid
degre
protect
strain
fcov
pretreat
hexamethylen
amilorid
provid
protect
viru
induc
cpe
similar
two
strain
reduct
cpe
fcov
respect
chloroquin
mefloquin
howev
effect
fcov
cpe
inhibit
chloroquin
versu
mefloquin
versu
strain
respect
studi
identifi
three
compound
chloroquin
mefloquin
hexamethylen
amilorid
demonstr
mark
inhibitori
effect
fcov
replic
vitro
signific
reduct
viru
induc
cpe
viral
titr
low
micromolar
concentr
present
earli
stage
viral
replic
antivir
effect
chloroquin
previous
demonstr
fcov
hexamethylen
amilorid
previous
demonstr
efficaci
coronavirus
howev
first
demonstr
antivir
efficaci
mefloquin
coronaviru
initi
compound
screen
perform
use
cpe
inhibit
assay
subsequ
viru
yield
reduct
assay
plaqu
reduct
assay
use
confirmatori
test
effect
compound
valu
correspond
select
index
vari
assay
method
utilis
unexpect
given
assay
measur
differ
endpoint
report
antivir
drug
retrovir
proteas
inhibitor
saquinavir
report
calcul
base
product
viral
antigen
approxim
lower
base
product
matur
virion
buss
cammack
similarli
variat
assay
condit
may
result
calcul
significantli
differ
valu
concentrationrespons
curv
chloroquin
sarscov
determin
use
pcr
base
viru
yield
reduct
assay
shown
shift
consider
right
viral
genom
copi
assay
day
postinfect
compar
day
postinfect
keyaert
et
al
similar
find
note
current
studi
chloroquin
mefloquin
differ
potenc
report
base
viru
yield
reduct
assay
perform
hpi
howev
seen
hexamethylen
amilorid
two
compound
ribavirin
rfeifnv
previous
demonstr
vitro
efficaci
fcov
fail
demonstr
signific
inhibit
cpe
screen
compound
discord
result
like
attribut
test
concentr
use
therapeut
rang
variat
assay
condit
sensit
compar
previou
work
screen
concentr
compound
use
studi
determin
base
cytotox
test
achiev
cell
viabil
greater
previou
studi
ribavirin
demonstr
valu
mg
ml
mm
barlough
scott
base
visual
assess
protect
cytopath
effect
mg
ml
mm
base
reduct
extracellular
viral
titr
weiss
oostromram
concentr
use
screen
mm
therefor
time
lower
previous
calcul
base
similar
assay
endpoint
result
current
studi
viru
yield
reduct
assay
appear
provid
sensit
assess
antivir
efficaci
cpe
inhibit
assay
valu
calcul
base
viral
titr
reduct
significantli
lower
calcul
base
cpe
inhibit
compound
small
antivir
effect
ribavirin
therefor
rule
base
current
find
although
test
concentr
provid
protect
viru
induc
cpe
may
associ
reduct
extracellular
viral
titr
practic
relev
small
antivir
effect
question
particularli
given
known
toxic
profil
compound
cat
rfeifnv
reduct
viral
titr
log
report
crfk
cell
treat
u
ml
h
postinfect
truyen
et
al
log
fcwf
cell
pretreat
u
rfeinfv
mochizuki
et
al
protect
cpe
seen
current
studi
cell
pretreat
rfeinfv
u
ml
concentr
significantli
lower
previous
shown
effect
use
viru
strain
cell
line
truyen
et
al
test
concentr
howev
similar
use
mochizuki
et
al
appar
lack
efficaci
case
may
reflect
differ
drug
exposur
infect
condit
viral
isol
test
intrins
enhanc
suscept
antivir
effect
interferon
fcwf
cell
compar
crfk
cell
use
studi
weiss
toiviokinnucan
altern
may
suggest
ribavirin
viru
yield
reduct
assay
provid
sensit
assess
antivir
effect
cpe
inhibit
assay
screen
method
utilis
fail
identifi
mild
antivir
effect
number
differ
mechan
action
suggest
account
antivir
properti
compound
identifi
studi
virus
chloroquin
antivir
effect
ascrib
inhibit
glycosyl
viral
protein
savarino
et
al
cellular
receptor
viral
attach
vincent
et
al
inhibit
glycoprotein
express
dill
johnson
inhibit
endosom
mediat
viral
entri
savarino
et
al
antivir
effect
mefloquin
jc
viru
postul
due
action
adenosin
mimet
brickelmai
et
al
hexamethylen
amilorid
suggest
antivir
properti
differ
virus
may
aris
competit
inhibit
viral
rna
polymeras
gazina
et
al
indirect
mutagen
effect
levi
et
al
inhibit
viroporin
wilson
et
al
interestingli
three
compound
show
mark
antivir
efficaci
fcov
studi
result
similar
morpholog
chang
cell
expos
subtox
concentr
increas
number
variabl
size
cytoplasm
inclus
accumul
viral
dye
neutral
red
suggest
compound
result
perturb
normal
endocyt
pathway
crfk
cell
alter
endocyt
pathway
previous
report
chloroquin
dean
et
al
mefloquin
labro
babinchevay
amilorid
deriv
dutta
donaldson
suggest
common
physiolog
effect
treat
cell
three
candid
antivir
possibl
share
mechan
action
virus
known
usurp
varieti
host
endocyt
pathway
cell
entri
intracellular
movement
inhibit
pathway
may
use
therapeut
approach
although
target
cellular
pathway
may
associ
increas
risk
toxic
pathway
critic
viral
replic
approach
may
slow
limit
develop
resist
time
addit
studi
demonstr
compound
effect
ad
prior
infect
suggest
mechan
action
involv
earli
stage
viral
replic
cpe
inhibit
base
time
addit
assay
involv
infect
low
moi
h
infect
period
allow
multipl
round
viral
replic
result
even
delay
addit
compound
cell
uninfect
origin
inoculum
effect
pretreat
prior
challeng
progeni
virion
produc
primari
replic
cycl
use
ifabas
time
addit
studi
involv
singl
replic
cycl
abl
clarifi
effect
time
addit
refin
possibl
stage
viral
life
cycl
target
compound
base
ifa
result
chloroquin
effect
present
time
infect
support
hypothesi
chloroquin
act
cell
entri
fcov
possibl
inhibit
endosom
ph
takano
et
al
hexamethylen
amilorid
mefloquin
provid
signific
antivir
effect
compound
addit
delay
hpi
respect
suggest
antivir
effect
compound
aris
perturb
endosom
function
effect
occur
differ
stage
viral
life
cycl
altern
distinct
mechan
action
may
account
observ
effect
compound
suggest
virus
limit
publish
pharmacokinet
safeti
data
inform
potenti
therapeut
applic
identifi
compound
cat
given
rel
low
si
three
compound
consider
must
given
vivo
safeti
speci
human
approv
pharmaceut
chloroquin
mefloquin
gener
consid
welltoler
drug
albeit
narrow
therapeut
index
clinic
use
hexamethylen
amilorid
report
pharmacokinet
data
avail
chloroquin
mefloquin
human
would
suggest
effect
plasma
concentr
could
achiev
standard
therapeut
dose
pussard
verdier
simpson
et
al
chloroquin
shown
accumul
leukocyt
concentr
may
two
order
magnitud
greater
plasma
mackenzi
highest
concentr
report
monocyt
french
et
al
thu
therapeut
concentr
may
attain
target
cell
virul
biotyp
fcov
rel
low
plasma
concentr
minimis
risk
dosedepend
advers
effect
mefloquin
known
accumul
within
brain
parenchyma
concentr
approxim
time
higher
found
serum
tissu
concentr
mm
report
nevin
pham
et
al
mefloquin
may
therefor
use
treatment
dri
noneffus
fip
cn
lesion
common
pedersen
although
potenti
neurotox
must
consid
although
concentr
mefloquin
achiev
cn
greater
compound
immortalis
felin
kidney
cell
human
tissu
concentr
achiev
therapeut
dose
despit
vitro
data
human
cell
show
approxim
equal
determin
current
studi
brickelmai
et
al
may
therefor
static
cell
popul
cn
refractori
toxic
effect
mefloquin
mitot
activ
immortalis
cell
studi
identifi
three
compound
demonstr
mark
vitro
inhibit
fcov
immortalis
cell
line
low
micromolar
concentr
includ
first
demonstr
antivir
effect
mefloquin
coronaviru
although
low
si
three
compound
may
limit
therapeut
util
preliminari
studi
open
way
investig
potenti
optimis
compound
antivir
agent
